Influenzinum
cGMP deviations
1,206 recalls · Class II, newest first
cGMP deviations
cGMP deviations
cGMP deviations
cGMP deviations
cGMP deviations
cGMP deviations
cGMP deviations
CGMP Deviations: Gaps in the quality system in the Quality Control microbiology laboratory.
CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits .
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits .
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits .
Subpotent Drug: FDA analysis has revealed some bottles of these products were sub potent for ethanol.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.
Lack of assurance of sterility.